Hypoxia-inducible factors

hypoxia-inducible factor 1, alpha subunit
Identifiers
Symbol	HIF1A
Entrez	3091
HUGO	4910
OMIM	603348
RefSeq	NM_001530
UniProt	Q16665
Other data
Locus	Chr. 14 q21-q24

aryl hydrocarbon receptor nuclear translocator
Identifiers
Symbol	ARNT
Alt. symbols	HIF1B, bHLHe2
Entrez	405
HUGO	700
OMIM	126110
RefSeq	NM_001668
UniProt	P27540
Other data
Locus	Chr. 1 q21

endothelial PAS domain protein 1
Identifiers
Symbol	EPAS1
Alt. symbols	HIF2A, MOP2, PASD2, HLF
Entrez	2034
HUGO	3374
OMIM	603349
RefSeq	NM_001430
UniProt	Q99814
Other data
Locus	Chr. 2 p21-p16

aryl-hydrocarbon receptor nuclear translocator 2
Identifiers
Symbol	ARNT2
Alt. symbols	HIF2B, KIAA0307, bHLHe1
Entrez	9915
HUGO	16876
OMIM	606036
RefSeq	NM_014862
UniProt	Q9HBZ2
Other data
Locus	Chr. 1 q24

hypoxia-inducible factor 3, alpha subunit
Identifiers
Symbol	HIF3A
Entrez	64344
HUGO	15825
OMIM	609976
RefSeq	NM_152794
UniProt	Q9Y2N7
Other data
Locus	Chr. 19 q13

Hypoxia-inducible factors (HIFs) are transcription factors that respond to changes in available oxygen in the cellular environment, to be specific, to decreases in oxygen, or hypoxia.

Structure

Most, if not all, oxygen-breathing species express the highly conserved transcriptional complex HIF-1, which is a heterodimer composed of an alpha and a beta subunit, the latter being a constitutively-expressed aryl hydrocarbon receptor nuclear translocator (ARNT). HIF-1 belongs to the PER-ARNT-SIM (PAS) subfamily of the basic helix-loop-helix (bHLH) family of transcription factors. The alpha and beta subunit are similar in structure and both contain the following domains:

• N-terminus – a bHLH domain for DNA binding
• central region – Per-ARNT-Sim (PAS) domain, which facilitates heterodimerization
• C-terminus – recruits transcriptional coregulatory proteins

Hypoxia-inducible factor-1 Structure of a HIF-1a-pVHL-ElonginB-ElonginC Complex. Identifiers Symbol HIF-1 Pfam PF11413 Available protein structures: Pfam structures PDB RCSB PDB; PDBe; PDBj PDBsum structure summary

HIF-1 alpha C terminal transactivation domain Structure of hypoxia-inducible factor-1 alpha subunit. Identifiers Symbol HIF-1a_CTAD Pfam PF08778 InterPro IPR014887 SCOP 1l3e SUPERFAMILY 1l3e Available protein structures: Pfam structures PDB RCSB PDB; PDBe; PDBj PDBsum structure summary

Members

The following are members of the human HIF family:

member	gene	protein
HIF-1α	HIF1A	hypoxia-inducible factor 1, alpha subunit
HIF-1β	ARNT	aryl hydrocarbon receptor nuclear translocator
HIF-2α	EPAS1	endothelial PAS domain protein 1
HIF-2β	ARNT2	aryl-hydrocarbon receptor nuclear translocator 2
HIF-3α	HIF3A	hypoxia inducible factor 3, alpha subunit
HIF-3β	ARNTL	aryl-hydrocarbon receptor nuclear translocator 3

Role

The HIF signaling cascade mediates the effects of hypoxia, the state of low oxygen concentration, on the cell. Hypoxia often keeps cells from differentiating. However, hypoxia promotes the formation of blood vessels, and is important for the formation of a vascular system in embryos, and cancer tumors. The hypoxia in wounds also promotes the migration of keratinocytes and the restoration of the epithelium.

In general, HIFs are vital to development. In mammals, deletion of the HIF-1 genes results in perinatal death. HIF-1 has been shown to be vital to chondrocyte survival, allowing the cells to adapt to low-oxygen conditions within the growth plates of bones. HIF plays a central role in the regulation of human metabolism.

Mechanism

The alpha subunits of HIF are hydroxylated at conserved proline residues by HIF prolyl-hydroxylases, allowing their recognition and ubiquitination by the VHL E3 ubiquitin ligase, which labels them for rapid degradation by the proteasome. This occurs only in normoxic conditions. In hypoxic conditions, HIF prolyl-hydroxylase is inhibited, since it utilizes oxygen as a cosubstrate.

Inhibition of electron transfer in the succinate dehydrogenase complex due to mutations in the SDHB or SDHD genes can cause a build-up of succinate that inhibits HIF prolyl-hydroxylase, stabilizing HIF-1α. This is termed pseudohypoxia.

HIF-1, when stabilized by hypoxic conditions, upregulates several genes to promote survival in low-oxygen conditions. These include glycolysis enzymes, which allow ATP synthesis in an oxygen-independent manner, and vascular endothelial growth factor (VEGF), which promotes angiogenesis. HIF-1 acts by binding to HIF-responsive elements (HREs) in promoters that contain the sequence NCGTG (where N is either A or G).

It has been shown that muscle A kinase–anchoring protein (mAKAP) organized E3 ubiquitin ligases, affecting stability and positioning of HIF-1 inside its action site in the nucleus. Depletion of mAKAP or disruption of its targeting to the perinuclear (in cardiomyocytes) region altered the stability of HIF-1 and transcriptional activation of genes associated with hypoxia. Thus, "compartmentalization" of oxygen-sensitive signaling components may influence the hypoxic response.

The advanced knowledge of the molecular regulatory mechanisms of HIF1 activity under hypoxic conditions contrast sharply with the paucity of information on the mechanistic and functional aspects governing NF-κB-mediated HIF1 regulation under normoxic conditions. However, HIF-1α stabilization is also found in non-hypoxic conditions through an, until recently, unknown mechanism. It was shown that NF-κB (nuclear factor κB) is a direct modulator of HIF-1α expression in the presence of normal oxygen pressure. siRNA (small interfering RNA) studies for individual NF-κB members revealed differential effects on HIF-1α mRNA levels, indicating that NF-κB can regulate basal HIF-1α expression. Finally, it was shown that, when endogenous NF-κB is induced by TNFα (tumour necrosis factor α) treatment, HIF-1α levels also change in an NF-κB-dependent manner. HIF-1 and HIF-2 have different physiological roles. HIF-2 regulates erythropoietin production in adult life.

Repair or regeneration

In normal circumstances after injury HIF-1a is degraded by prolyl hydroxylases (PHDs). In June 2015, scientists found that the continued up-regulation of HIF-1a via PHD inhibitors regenerates lost or damaged tissue in mammals that have a repair response; and the continued down-regulation of Hif-1a results in healing with a scarring response in mammals with a previous regenerative response to the loss of tissue. The act of regulating HIF-1a can either turn off, or turn on the key process of mammalian regeneration.

As a therapeutic target

Anemia

Recently, several drugs that act as selective HIF prolyl-hydroxylase inhibitors have been developed. The most notable of these include FibroGen's compounds FG-2216 and FG-4592, both of which intended as orally acting drugs for use in the treatment of forms of anemia. By inhibiting HIF prolyl-hydroxylase, the stability of HIF-2α in the kidney is increased, which results in an increase in endogenous production of erythropoietin. Both of these drugs made it through to phase II clinical trials, but these were suspended temporarily in May 2007 following the death of a trial participant from fulminant hepatitis. However, it is unclear whether this death was caused by FG-2216. The hold has been lifted in early 2008, as FDA has reviewed and approved a thorough response from FibroGen.

Inflammation and cancer

In other scenarios and in contrast to the therapy outlined above, recent research suggests that HIF induction in normoxia is likely to have serious consequences in disease settings with a chronic inflammatory component. It has also been shown that chronic inflammation is self-perpetuating and that it distorts the microenvironment as a result of aberrantly active transcription factors. As a consequence, alterations in growth factor, chemokine, cytokine, and ROS balance occur within the cellular milieu that in turn provide the axis of growth and survival needed for de novo development of cancer and metastasis. The results of a recently published study have numerous implications for a number of pathologies where NF-κB and HIF-1 are deregulated, including rheumatoid arthritis and cancer. Therefore, it is thought that understanding the cross-talk between these two key transcription factors, NF-κB and HIF, will greatly enhance the process of drug development.

HIF activity is involved in angiogenesis required for cancer tumor growth, so HIF inhibitors such as phenethyl isothiocyanate and Acriflavine are (since 2006) under investigation for anti-cancer effects.

Neurology

Research conducted on mice suggests that stabilizing HIF using an HIF prolyl-hydroxylase inhibitor enhances hippocampal memory, likely by increasing erythropoietin expression.

See also

• HIF-1α

External links

• Hypoxia-Inducible Factor 1 at the US National Library of Medicine Medical Subject Headings (MeSH)